Late 2022, CIVCO RT and Qfix announced the merger of their two companies to become a joint manufacturer offering the best of both product ranges - "Better Together". Gamma Gurus is very pleased to announce that we have been selected to carry both Qfix and CIVCO RT lines in the Australian and New Zealand markets. We look forward to offering expanded options for our customers such as the innovative Alta™, Access™ & Encompass™ (validated for HyperArc™). Qfix – Gamma Gurus
Gamma Gurus is very pleased to announce the signing of an agency agreement with Bruker BioSpin to market their portfolio of Nuclear Molecular Imaging (NMI) products in Australia & New Zealand. This expands our ability to support the preclinical NMI field by adding additional products, including PET/MR, to the already successful Molecubes range that was acquired by Bruker in November 2021. We look forward to introducing these new products to our customers in 2023!
RadTat is the first non-invasive, semi-permanent skin marking for radiation oncology and Gamma Gurus is pleased to be able to offer this innovative product in Australia. RadTats were designed with both patients and providers in mind as a simple and painless alternative to permanent tatoos that will last for up to two weeks with little to no maintenance by patient or care provider. This is not a sticker! RadTat provides a quick, simple solution that lasts! RadTat Semi-permanent Skin Marking – Gamma Gurus
Gamma Gurus is extremely pleased to announce that they have been appointed sales agents for IBA Proton Therapy products in Australia & New Zealand. IBA is the world leader in Proton Therapy with over 56% of patients worldwide being treated on IBA systems. Currently there are no Proton Therapy centres operating in Australasia and we are very excited about helping to bring this technology to the region. The addition of IBA Proton Therapy also complements Gamma Gurus' existing portfolio of particle therapy solutions which include C-RAD Surface Guidance systems, CIVCO Patient Positioning and Immobilisation, IBA Dosimetry, and NELCO Radiation Doors...
MIM Software has been leading the way in Theranostics dosimetry for some time and they have just upped the ante with AI-based segmentation and single time-point dosimetry. Contact us to talk about how these new features can help save time both for your patients. MIM Software Inc. Announces AI Segmentation and Single Timepoint Dosimetry Capabilities for Molecular Radiotherapy:https://www.prnewswire.co.uk/news-releases/mim-software-inc-announces-ai-segmentation-and-single-timepoint-dosimetry-capabilities-for-molecular-radiotherapy-818159290.html